Developing biomarkers to detect and predict outcomes of early-stage lung cancer
Official title: Microbial and host biomarker development for detection and prognosis of early stage non-small cell lung cancer
Funded at New York University School of Medicine · NIH-11081756 · Data updated 2026-11-12
This study is looking for helpful signs in blood and lung samples that can spot non-small cell lung cancer early and tell if a lung nodule is cancerous or not, which could lead to better treatment for patients with early-stage lung cancer.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | May 4, 2023 |
| Project end | April 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $1,019,623 |
| NIH project number | 5U2CCA271890-03 |
| Project ID | NIH-11081756 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with early-stage non-small cell lung cancer or those with indeterminate lung nodules.
✕Less likely to help
Patients with advanced-stage lung cancer or those without lung nodules may not receive benefit from this research.
What this research studies
This research focuses on identifying microbial and host biomarkers that can help in the early detection and prognosis of non-small cell lung cancer (NSCLC). By analyzing blood samples and lower airway signatures, the study aims to develop non-invasive diagnostic tools that can accurately differentiate between malignant and non-malignant lung nodules. The approach utilizes advanced techniques to characterize the microbiome and identify RNA signatures associated with lung cancer, potentially leading to better patient outcomes. Patients with early-stage NSCLC may benefit from these findings, which could improve diagnostic accuracy and treatment strategies.
Why it matters
Potential benefit: If successful, this research could lead to more accurate and less invasive methods for diagnosing lung cancer and predicting patient outcomes.
How similar studies have gone: Other research has shown promise in using microbial signatures for cancer diagnosis, suggesting that this approach could be effective.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Segal, Leopoldo Nicolas — New York University School of Medicine
- Study coordinator: Segal, Leopoldo Nicolas
Related research
Other NIH-funded projects on the same topics.
-
Blood and airway microbe and gene tests to find and predict early non-small cell lung cancer
This project looks for microbial and host gene signals in blood and airway samples to help spot early non-small cell lung cancer and predict who might have the cancer come back.
-
Predicting cancer recurrence and treatment benefits for early-stage lung cancer patients
This study is working on a new test that looks at 7 specific genes to help predict if early-stage lung cancer might come back after surgery and to see if extra chemotherapy could be helpful for patients who have had surgery for stage 1 non-small cell lung cancer.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
-
Targeting STRAP to curb NSCLC spread with nanoparticle therapy
Aimed at non-small cell lung cancer, this grant tests how blocking a protein called STRAP with nanoparticles could slow cancer spread and make chemotherapy work better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.